Lamivudine + Tenofovir Disoproxil Fumarate + Nevirapine Co-PackThird Party Manufacturing in India

Lamivudine + Tenofovir Disoproxil Fumarate + Nevirapine Co-Pack is a three-drug antiretroviral co-pack containing two nucleoside analogue reverse transcriptase inhibitors and one non-nucleoside reverse transcriptase inhibitor, providing complete triple-drug therapy for HIV-1 infection. Lamivudine is a cytidine analogue that is phosphorylated intracellularly to its active triphosphate form, which inhibits HIV reverse transcriptase by competing with natural nucleotides and causing chain termination when incorporated into viral DNA. Tenofovir Disoproxil Fumarate is a prodrug of tenofovir, an acyclic nucleoside phosphonate that undergoes phosphorylation to tenofovir diphosphate, which inhibits reverse transcriptase through competitive inhibition and chain termination. As a phosphonate prodrug, tenofovir achieves higher intracellular active metabolite concentrations by bypassing the first phosphorylation step required for other NRTIs. Nevirapine is a non-nucleoside reverse transcriptase inhibitor that binds directly to a hydrophobic pocket on the HIV-1 reverse transcriptase enzyme near the active site, causing a conformational change that disrupts the catalytic function of the enzyme. Unlike NRTIs, nevirapine does not require intracellular phosphorylation and acts directly on the enzyme. By combining two NRTIs with one NNRTI, this co-pack provides potent viral suppression through three distinct mechanisms, effectively reducing viral load to undetectable levels and preventing the emergence of drug-resistant viral strains.

Therapeutic Uses

Lamivudine + Tenofovir Disoproxil Fumarate + Nevirapine Co-Pack is prescribed for the treatment of:

• HIV-1 Infection in Adults and Adolescents: This three-drug regimen is indicated as a complete antiretroviral therapy for the treatment of HIV-1 infection, suitable for treatment-naive patients starting antiretroviral therapy.
• Prevention of Mother-to-Child Transmission: Nevirapine-based regimens are widely used in resource-limited settings for the prevention of vertical HIV transmission from mother to infant.
• Resource-Limited Settings: The co-pack format is specifically designed for large-scale distribution in public health programmes, simplifying supply chain logistics and improving patient adherence through clear packaging and dosing instructions.
• HIV Post-Exposure Prophylaxis: The triple-drug combination provides robust prophylactic coverage following significant occupational or non-occupational HIV exposure.

Why Manufacturers Choose Lamivudine + Tenofovir Disoproxil Fumarate + Nevirapine Co-Pack

This triple-drug antiretroviral co-pack has been a cornerstone of WHO-recommended first-line HIV therapy for decades, particularly in resource-limited settings where large-scale government procurement programmes drive consistent, high-volume demand. The co-pack format, containing lamivudine 300 mg, tenofovir DF 300 mg, and nevirapine 200 mg in a single convenient pack, simplifies distribution and improves treatment adherence. Indian manufacturers have extensive experience producing and supplying this regimen to international procurement agencies, including the Global Fund, PEPFAR, and UNITAID. The product's inclusion in WHO Essential Medicines List and its continued role in national HIV treatment programmes across Africa and Asia ensures sustained long-term demand. This makes Lamivudine + Tenofovir Disoproxil Fumarate + Nevirapine Co-Pack one of the most sought-after molecules for third party manufacturing in India, with consistent demand from PCD franchise operators and export-oriented companies.